← Russell 3000 cross-section

NPCE NeuroPace Inc

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$504m
Revenue TTM
$99m
Net income TTM
$-19m
Free cash flow
$-12m
Composite score
38.5
Sector rank
#2397

Valuation

P / E
EV / EBITDA
EV / sales
5.2
FCF yield
-2.30%
Earnings yield vs 10-yr
-8.52pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-19.3%
EBITDA margin
-15.0%
ROE
-160.8%
ROIC
-78.5%
Revenue growth
11.6%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We have financed our operations primarily through sales of our products, issuance of equity securities, and debt financing. We have also made significant investments in building our field commercial team and intend to make significant investments in sales and marketing efforts in the future, including initiatives to drive awareness and expand our referral channel to increase the number of drug-resistant epilepsy patients referred to CECs. Our revenue fluctuates primarily based on the volume of procedures performed and the procedure mix between initial and replacement implants. …NeuroPace Inc, 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →